Glynib Ingredients and Usage

The active ingredient is Imatinib Mesylate, a protein-tyrosine kinase inhibitor that specifically targets BCR-ABL tyrosine kinase. The 100mg tablet is taken with a meal and large glass of water, with dosage and frequency determined by the specific cancer type, disease phase, and individual patient response.

Glynib is clinically indicated for:

• Newly diagnosed chronic myeloid leukemia (CML) in chronic phase
• CML in accelerated phase or blast crisis
• Kit (CD117)-positive gastrointestinal stromal tumors (GIST)
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
• Myelodysplastic/myeloproliferative diseases
• Dermatofibrosarcoma protuberans

How Does Glynib Work?

Glynib provides targeted anti-cancer action through specific kinase inhibition:

1. BCR-ABL Inhibition: Specifically inhibits BCR-ABL tyrosine kinase in CML cells
2. Kit Receptor Blockade: Inhibits Kit receptor tyrosine kinase in GIST tumors
3. PDGFR Inhibition: Blocks platelet-derived growth factor receptor activity
4. Selective Action: Targets abnormal kinases while sparing normal cellular functions

Glynib Side Effects and Warnings

Common side effects include edema, nausea, vomiting, muscle cramps, rash, fatigue, diarrhea, and hematological toxicity. Most adverse effects are manageable with dose adjustments and supportive care.

Serious Considerations

1. Fluid Retention: May cause severe fluid retention and pleural effusion
2. Hematologic Toxicity: Can cause severe neutropenia and thrombocytopenia
3. Hepatic Toxicity: May cause severe liver injury – monitor liver function regularly
4. Cardiac Toxicity: Risk of congestive heart failure and left ventricular dysfunction
5. Growth Retardation: May cause growth retardation in children and adolescents

Glynib Storage Conditions

Glynib Tablets require proper storage conditions:

• Store below 30°C in original container
• Keep the bottle tightly closed
• Protect from moisture and light
• Keep out of reach of children
• Do not use after expiration date